Anti-tick vaccines in the omics era.

Anti-tick vaccines in the omics era. Front Biosci (Elite Ed). 2018 Jan 01;10:122-136 Authors: Valle MR, Guerrero FD Abstract Tick vaccines have been available for more than 20 years. They are useful and effective control agents when used properly. However, no new products have emerged since the Bm86-based Gavac vaccine was commercialized. Acaricide resistance is a problem with no abatement in sight and anti-tick vaccines are likely to be relied upon even more in the coming years. As human medicine and plant agriculture has embraced the various Omics technologies, the search for anti-tick vaccines would be well served to follow; so that new vaccine antigens and adjuvants might be developed to assist tick control programs. However, the simple outward appearance of ticks and their life cycle belies the complexity of their genomes which are computationally challenging to sequence and annotate. We review various Omics research efforts in light of research on anti-tick vaccines. PMID: 28930608 [PubMed - in process]
Source: Frontiers in Bioscience - Elite - Category: Biomedical Science Tags: Front Biosci (Elite Ed) Source Type: research

Related Links:

Authors: Zhang N, Wang H, Yang J PMID: 32100488 [PubMed - in process]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
Publication date: Available online 26 February 2020Source: Antiviral ResearchAuthor(s): Hyeon Cheol Kim, Dong Sun Oh, Jang Hyun Park, Hyun-Jin Kim, Yong Bok Seo, Hye Jee Yoo, Hye Seon Jang, Jua Shin, Chae Won Kim, Myeong Seung Kwon, Hyun-Tak Jin, Sung Ki Lee, Ji Eun Oh, Heung Kyu Lee
Source: Antiviral Therapy - Category: Virology Source Type: research
Publication date: April 2020Source: Current Opinion in Virology, Volume 41Author(s): Peter J Hotez, Tasmiah Nuzhath, Brian Colwell
Source: Current Opinion in Virology - Category: Virology Source Type: research
In this study, we investigated low pH inactivation of viruses including PCV Type 1 (PCV1) and PCV1 removal by cation exchange chromatography (CEX) in the presence of pepsin. Both parvovirus and PCV1 could be effectively inactivated by low pH and PCV1 could be removed by POROS 50HS CEX. The POROS 50HS method presented in this article is helpful for designing other CEX methods for the same purpose and not much difference would be expected for similar product intermediates and same process parameters. While the effectiveness needs to be confirmed for specific applications, the results demonstrate that both low pH (pH 1...
Source: Biotechnology Progress - Category: Biotechnology Authors: Tags: Research Article Source Type: research
CONCLUSION: Overall, 13 new signals of PPSVs, including four signals not listed on the labels, were detected. Further research based on additional AE reports is required to confirm the validity of these signals for children. PMID: 32102125 [PubMed - as supplied by publisher]
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
Funding Opportunity RFA-AI-20-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support development of promising universal influenza vaccine candidates that protect against both influenza A and B viruses.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
The rapid spread of the coronavirus now called COVID-19 has sparked alarm worldwide. The World Health Organization (WHO) has declared a global health emergency, and many countries are grappling with a rise in confirmed cases. In the US, the Centers for Disease Control and Prevention (CDC) is advising people to be prepared for disruptions to daily life that will be necessary if the coronavirus spreads within communities. Below, we’re responding to a number of questions about COVID-19 raised by Harvard Health Blog readers. We hope to add further questions and update answers as reliable information becomes available. Do...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Children's Health Cold and Flu Infectious diseases Men's Health Women's Health Source Type: blogs
Birmingham-based Southern Research has entered into a strategic collaboration with New York-based clinical-stage biopharmaceutical company Tonix Pharmaceuticals to support the development of a vaccine against the new coronavirus disease, COVID-19.   The vaccine is based on Tonix’s proprietary horsepox vaccine platform, TNX-801. The vaccine has been developed as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a vaccine against monkeypox. According to Southern…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
As the coronavirus spreads, Novavax Inc. is moving forward to find a defense against it. The Gaithersburg company, which a month ago set out to develop a vaccine for the COVID-19 coronavirus, is now evaluating candidates in animal models — a critical step toward testing in humans. Now Novavax (NASDAQ: NVAX) hopes to receive Food and Drug Administration approval to start human clinic al trials by the end of this spring, it said Wednesday, a fast timeline relative to the years-long research and development…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
A CDC advisory committee recommended preexposure vaccination with the first-ever FDA-approved vaccine against Ebola virus, species Zaire ebolavirus, for three groups of high-risk adults.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
More News: Biomedical Science | Eyes | Vaccines